1. Current pharmacotherapy of overactive bladder
- Author
-
Evgenyi I Kreydin, Cristiano Mendes Gomes, and Francisco Cruz
- Subjects
Male ,medicine.medical_specialty ,Urology ,Adrenergic beta-3 Receptor Agonists ,Urinary incontinence ,Review Article ,Muscarinic Antagonists ,urologic and male genital diseases ,Pharmacotherapy ,Drug Therapy ,Quality of life ,medicine ,Humans ,Dosing ,Intensive care medicine ,Antimuscarinic Agent ,Urinary Bladder, Overactive ,business.industry ,medicine.disease ,Diseases of the genitourinary system. Urology ,Treatment Outcome ,Urinary Incontinence ,Tolerability ,Overactive bladder ,Quality of Life ,Female ,RC870-923 ,medicine.symptom ,Mirabegron ,business ,medicine.drug - Abstract
Overactive bladder is a symptom complex consisting of bothersome storage urinary symptoms that is highly prevalent among both sexes and has a significant impact on quality of life. Various antimuscarinic agents and the beta-3 agonists mirabegron and vibegron are currently available for the treatment of OAB. Each drug has specific pharmacologic properties, dosing schedule and tolerability profile, making it essential to individualize the medical treatment for the patient's characteristics and expectations. In this manuscript, we review the most important factors involved in the contemporary pharmacological treatment of OAB.
- Published
- 2021
- Full Text
- View/download PDF